Business Context and Reporting Period
This Form 8-K Current Report was filed by Alkermes Plc. on September 14, 2026. The filing reports a corporate governance event: the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Board Expansion: The Board of Directors increased its size from 10 to 11 members.
- New Appointment: Anne C. Whitaker was appointed as a director, effective immediately, with a term expiring at the 2027 annual general meeting.
- Committee Assignments: As of the filing date, Ms. Whitaker has not been appointed to any Board committee.
Compensation, Outlook, and Risks
Compensation Arrangements:
- Annual Retainer: Ms. Whitaker will receive an annual cash retainer and equity grant determined by the processes in the Company's definitive proxy statement filed on April 6, 2026.
- Initial Equity Award: An initial new director equity award with an aggregate target value of $600,000 will be granted. This consists of 50% stock options and 50% restricted stock units (RSUs).
- Vesting Schedule: The award will vest in three equal annual installments commencing on the first anniversary of the grant date, subject to continuous service.
- Grant Timing: The award is expected to be granted in October 2026 on the monthly new hire employee grant date.
- Exercise Price: The exercise price for stock options will equal the closing price of the Company's ordinary shares on the grant date.
Legal Agreements: The Company and its subsidiary, Alkermes, Inc., have entered into indemnification agreements with Ms. Whitaker.
Related Transactions: Ms. Whitaker has not participated in any transactions with the Company since January 1, 2025, requiring disclosure under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the specific annual cash retainer amount in the definitive proxy statement filed on April 6, 2026.
- Confirm the exact grant date in October 2026 to determine the final exercise price for the stock options.
- Review the press release (Exhibit 99.1) for additional context on Ms. Whitaker's background and qualifications.
- Monitor future filings for Ms. Whitaker's committee assignments.